FDA
-
-
-
-
-
-
-
Spruce Biosciences to Participate in Upcoming Conferences in June
-
-
-
-
-
-
-
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team
-
-
-
-
-
-
-
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)
-
-
-
-
-
-
-
Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH
-
-
-
-
-
-
-
Spruce Biosciences Provides Corporate Update and Outlines Milestones for 2021
-
323,114 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

